ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
IPO Year: 1992
Exchange: NASDAQ
Website: icumed.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/14/2024 | $183.00 | Hold | Jefferies |
6/21/2024 | Hold | Needham | |
6/17/2024 | $135.00 | Mkt Perform → Outperform | Raymond James |
11/8/2022 | Outperform → Mkt Perform | Raymond James | |
2/28/2022 | $286.00 → $265.00 | Outperform | Raymond James |
10/22/2021 | $302.00 → $280.00 | Overweight | Keybanc |
9/9/2021 | $220.00 → $286.00 | Outperform | Raymond James |
9/9/2021 | $225.00 → $302.00 | Overweight | Keybanc |
8/6/2021 | $236.00 → $225.00 | Overweight | Keybanc |
8/5/2021 | $245.00 → $220.00 | Outperform | Raymond James |
Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G - ICU MEDICAL INC/DE (0000883984) (Subject)
NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt
SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP gross profit for the third quarter of 2024 was $204.9 million, as compared to $183.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2024 was 34.8%, as compared to 33.2% in the same period in the prior year. GAAP net loss for the third quarter of 2024
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call. The Company will release its third quarter 2024 results on Tuesday, November 12th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, November 12th, 2024. The call can be accessed at (800) 343-5172, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com
SAN CLEMENTE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2024. Second Quarter 2024 Results Second quarter 2024 revenue was $596.5 million, compared to $549.3 million in the same period in the prior year. GAAP gross profit for the second quarter of 2024 was $207.4 million, as compared to $192.3 million in the same period in the prior year. GAAP gross margin for the second quarter of 2024 and 2023 was 35%. GAAP net loss for the second quarter of 2024 was $(21.4) million, or $(0.88) per diluted share, as c
SAN CLEMENTE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2024 earnings release and conference call. The Company will release its second quarter 2024 results on Wednesday, August 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, August 7th, 2024. The call can be accessed at (800) 579-2543, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the C
SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024. First Quarter 2024 Results First quarter 2024 revenue was $566.7 million, compared to $568.6 million in the same period in the prior year. GAAP gross profit for the first quarter of 2024 was $185.2 million, as compared to $192.0 million in the same period in the prior year. GAAP gross margin for the first quarter of 2024 was 33%, as compared to 34% in the same period in the prior year. GAAP net loss for the first quarter of 2024 was $(39.5)
SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. The call can be accessed at (800) 717-1738, conference ID 1112534. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websi
SAN CLEMENTE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2023 was 29%, as compared to 30% in the same period in the prior year. GAAP net loss for the fourth quarter of 2023
SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call. The Company will release its fourth quarter 2023 results on Tuesday, February 27th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, February 27th, 2024. The call can be accessed at (833) 816-1376, conference ID 10186026. The conference call will be simultaneously available by webcast, which can be accessed by going to the
SAN CLEMENTE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 Results Third quarter 2023 revenue was $553.3 million, compared to $597.9 million in the same period last year. GAAP gross profit for the third quarter of 2023 was $183.9 million, as compared to $186.4 million in the same period last year. GAAP gross margin for the third quarter of 2023 was 33%, as compared to 31% in the same period last year. GAAP net income for the third quarter of 2023 was $7.2 million, or $0.30 per diluted
SAN CLEMENTE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2023 earnings release and conference call. The Company will release its third quarter 2023 results on Monday, November 6th, 2023 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, November 6th, 2023. The call can be accessed at (833) 816-1376, conference ID 10182943. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. Joint venture becomes part of a global manufacturing network with scale and redundancyIntends to add long-term supply resiliency and accelerate IV solutions new product development in North AmericaCombines Otsuka Pharmaceutical Factory, Inc.'s expertise and global manufacturing scale with ICU Medical's strong North American production and distributionICU Medical to provide commercial services to the joint ventureExpected to becom
SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP gross profit for the third quarter of 2024 was $204.9 million, as compared to $183.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2024 was 34.8%, as compared to 33.2% in the same period in the prior year. GAAP net loss for the third quarter of 2024
SAN CLEMENTE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the UBS Global Healthcare Conference being held in Rancho Palos Verdes, California, November 11-14, 2024. ICU Medical's presentation will be on Wednesday, November 13, 2024 at 4:15 p.m. PT (7:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, November 13, 2024. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the E
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call. The Company will release its third quarter 2024 results on Tuesday, November 12th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, November 12th, 2024. The call can be accessed at (800) 343-5172, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com
SAN CLEMENTE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September: Wells Fargo 2024 Healthcare Conference on September 4, 2024 Vivek Jain, Chief Executive Officer, will attend one-on-one meetings at the Wells Fargo 2024 Healthcare Conference in Boston on Wednesday, September 4, 2024. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 Vivek Jain, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in N
SAN CLEMENTE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2024. Second Quarter 2024 Results Second quarter 2024 revenue was $596.5 million, compared to $549.3 million in the same period in the prior year. GAAP gross profit for the second quarter of 2024 was $207.4 million, as compared to $192.3 million in the same period in the prior year. GAAP gross margin for the second quarter of 2024 and 2023 was 35%. GAAP net loss for the second quarter of 2024 was $(21.4) million, or $(0.88) per diluted share, as c
SAN CLEMENTE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2024 earnings release and conference call. The Company will release its second quarter 2024 results on Wednesday, August 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, August 7th, 2024. The call can be accessed at (800) 579-2543, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the C
SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024. First Quarter 2024 Results First quarter 2024 revenue was $566.7 million, compared to $568.6 million in the same period in the prior year. GAAP gross profit for the first quarter of 2024 was $185.2 million, as compared to $192.0 million in the same period in the prior year. GAAP gross margin for the first quarter of 2024 was 33%, as compared to 34% in the same period in the prior year. GAAP net loss for the first quarter of 2024 was $(39.5)
SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. The call can be accessed at (800) 717-1738, conference ID 1112534. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websi
SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024. ICU Medical's presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
SD - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
ARS - ICU MEDICAL INC/DE (0000883984) (Filer)
Jefferies initiated coverage of ICU Medical with a rating of Hold and set a new price target of $183.00
Needham initiated coverage of ICU Medical with a rating of Hold
Raymond James upgraded ICU Medical from Mkt Perform to Outperform and set a new price target of $135.00
Raymond James downgraded ICU Medical from Outperform to Mkt Perform
Raymond James reiterated coverage of ICU Medical with a rating of Outperform and set a new price target of $265.00 from $286.00 previously
Keybanc reiterated coverage of ICU Medical with a rating of Overweight and set a new price target of $280.00 from $302.00 previously
Raymond James reiterated coverage of ICU Medical with a rating of Outperform and set a new price target of $286.00 from $220.00 previously
Keybanc reiterated coverage of ICU Medical with a rating of Overweight and set a new price target of $302.00 from $225.00 previously
Keybanc reiterated coverage of ICU Medical with a rating of Overweight and set a new price target of $225.00 from $236.00 previously
Raymond James reiterated coverage of ICU Medical with a rating of Outperform and set a new price target of $220.00 from $245.00 previously
Needham analyst Mike Matson initiates coverage on ICU Medical (NASDAQ:ICUI) with a Hold rating.
Raymond James analyst Jayson Bedford upgrades ICU Medical (NASDAQ:ICUI) from Market Perform to Outperform and announces $135 price target.
U.S. stocks were mixed, with the Dow Jones gaining around 100 points on Thursday. Shares of Spectrum Brands Holdings, Inc. (NYSE:SPB) rose sharply during Thursday's session following upbeat earnings. Spectrum Brands posted adjusted earnings of $1.62 per share, beating expectations of 62 cents per share. The company's quarterly sales came in at $718.50 million versus estimates of $707.52 million, according to data from Benzinga Pro. Spectrum Brands shares surged 12.4% to $95.00 on Thursday. Here are some other big stocks recording gains in today's session. Sezzle Inc. (NASDAQ:SEZL) shares climbed 69.9% to $75.99 after the company reported a year-over-year increase in first-qu
ICU Medical (NASDAQ:ICUI) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.82 by 17.07 percent. This is a 44.83 percent decrease over earnings of $1.74 per share from the same period last year. The company reported quarterly sales of $566.655 million which beat the analyst consensus estimate of $552.250 million by 2.61 percent. This is a 0.35 percent decrease over sales of $568.649 million the same period last year.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) from $55 to $59. Oppenheimer analyst Francois Brisebois reiterated an Outperform rating. Tarsus Pharmaceuticals shares gained 18.3% to close at $39.22 on Tuesday. See how other analysts view this stock. Wedbush increased the price target for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) from $60 to $67. Wedbush analyst Laura Chico maintained a Neutral rating. Apellis Pharmaceuticals shares fell 3.3% to close at $69.3
Keybanc analyst Brett Fishbin maintains ICU Medical (NASDAQ:ICUI) with a Overweight and raises the price target from $134 to $136.
For Fiscal Year 2024 the Company estimates GAAP net loss to be in the range of $(88) to $(71) and GAAP diluted loss per share estimated to be in the range of $(3.57) to $(2.87). The Company expects adjusted EBITDA to be in the range of $330 million to $370 million.
ICU Medical (NASDAQ:ICUI) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ICU Medical beat estimated earnings by 32.0%, reporting an EPS of $1.57 versus an estimate of $1.19. Revenue was up $9.84 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.19 which was followed by a 17.0% drop in the share price the next day. Here's a look at ICU Medical's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate 1.38 1.55 1.43 1.56 EPS Actual 1.57 1.88 1.74 1.60 Revenue Estimate 565.75M 562.90M 565.30M 578.77M Revenue Actua
ICU Medical (NASDAQ:ICUI) reported quarterly earnings of $1.57 per share which beat the analyst consensus estimate of $1.19 by 31.93 percent. The company reported quarterly sales of $587.86 million which beat the analyst consensus estimate of $563.02 million by 4.41 percent. This is a 1.70 percent increase over sales of $578.01 million the same period last year.